Considering benefits and harms of duloxetine for treatment of stress urinary incontinence: a meta-analysis of clinical…
Worth asking your prescriber to walk through early warning signs of agitation or activation when starting duloxetine, since this analysis found such events were about as common as the benefit.
Top of the evidence hierarchy, independently funded. how we score evidence
Caveat on this rating: Analysis of EMA clinical study reports by Nordic Cochrane Centre authors who are prominent critics of industry trial reporting; stress urinary incontinence is not an FDA-approved duloxetine indication, and the authors concluded harms outweighed benefits for that use.
In 4 placebo-controlled trials (1,913 women) of duloxetine for stress urinary incontinence — a European approval, not a US one — 1 in 8 rated themselves much or very much better (NNT 8, 95% CI 6 to 13), but 1 in 7 stopped treatment because of adverse events (NNH 7, 95% CI 6 to 8) and 1 in 7 experienced activation-type events the authors linked to potential suicidality risk (NNH 7, 95% CI 6 to 9).
Worth asking
Worth asking your prescriber to walk through early warning signs of agitation or activation when starting duloxetine, since this analysis found such events were about as common as the benefit.
What it is FDA approved for
Read off the label. Trial duration and approval year are shown only where they were recorded — never inferred.
- Major depressive disorder (adults)
- Generalized anxiety disorder (adults and pediatric patients 7 years and older)
- Diabetic peripheral neuropathic pain (adults)
- Fibromyalgia (adults and pediatric patients 13 years and older)
- Chronic musculoskeletal pain (adults)
Source
Considering benefits and harms of duloxetine for treatment of stress urinary incontinence: a meta-analysis of clinical study reports — Maund E, Guski LS, Gøtzsche PC (2017)
Reputable peer-reviewed journal
Read the source: https://doi.org/10.1503/cmaj.151104
DOI: 10.1503/cmaj.151104
How this was scored
- Study design
- Meta-analysis of randomised trials
- Funding
- Independently funded
- Published in
- Reputable peer-reviewed journal
- Sample size
- 1,913
- Preregistered
- No
- Conflicts disclosed
- Yes
- Independent of proponent
- Yes
- Retracted
- No
Read the full scoring rubric, including what it can't tell you.
Published August 19, 2026.
Questions
How strong is the evidence behind this?
Resolv rates this source "gold standard". Top of the evidence hierarchy, independently funded. It scores 89 out of 100 on our published rubric. One caveat travels with that badge: Analysis of EMA clinical study reports by Nordic Cochrane Centre authors who are prominent critics of industry trial reporting; stress urinary incontinence is not an FDA-approved duloxetine indication, and the authors concluded harms outweighed benefits for that use. The score is calculated from recorded facts about the source — study design, funding, publication venue, sample size, preregistration — not typed in by an editor.
What is the source for this?
Considering benefits and harms of duloxetine for treatment of stress urinary incontinence: a meta-analysis of clinical study reports — Maund E, Guski LS, Gøtzsche PC (2017). Published in: Reputable peer-reviewed journal. DOI: 10.1503/cmaj.151104. The full source is linked on this page so you can read it yourself.
Who paid for this research, and does that matter?
Study design: Meta-analysis of randomised trials. Funding: Independently funded. The researchers were independent of whoever benefits from the result. Industry sponsorship is one of the most reliably measured biases in medicine, which is why funding carries real weight in the score rather than sitting in a footnote.
Is duloxetine (Cymbalta), cymbalta FDA approved?
Yes — FDA approved for Major depressive disorder (adults), Generalized anxiety disorder (adults and pediatric patients 7 years and older), Diabetic peripheral neuropathic pain (adults), Fibromyalgia (adults and pediatric patients 13 years and older), Chronic musculoskeletal pain (adults). Approval is for a specific indication, not for everything the drug is prescribed for.
Is this medical advice?
This is information to bring to your prescriber, not medical advice and not a reason to change anything on your own. Nothing here is an instruction to stop or reduce a medication. If you are in crisis, call or text 988.
This is information to bring to your prescriber, not medical advice and not a reason to change anything on your own. Nothing here is an instruction to stop or reduce a medication. If you are in crisis, call or text 988.